Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation in rabbits

Drugs in R and D

Volumn 6, Issue 1, 2005, Pages 11-19

  Gamez R ^a   Mas R ^a   Arruzazabala, M L ^a   Mendoza, S ^a   Castano G ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANOL; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; DOTRIACONTANOL; HEPTACOSANOL; HEXACOSANOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONACOSANOL; OCATACOSANOL; OMEGA 3 FATTY ACID; POLICOSANOL; TETRACOSANOL; TETRAICONTANOL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG FORMULATION; DRUG TOLERABILITY; FOOD INTAKE; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANIMALS; BODY WEIGHT; CHOLESTEROL; DRUG SYNERGISM; EATING; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FATTY ALCOHOLS; LIPIDS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RABBITS; TRIGLYCERIDES;

EID: 13844318280     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200506010-00002     Document Type: Article

References (58)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351-64
2. Lipid Research Clinic Program. The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in the incidence of coronary heart disease to cholesterol-lowering. JAMA 1984; 251: 365-74
3. Frick MH, Elo O, Happa K. Helsinki Heart Study: primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237-45
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
5. Sacks FM, Pfeffer MA, Moyé LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
7. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
8. Downs JR, Clearfield M, Weiss S, et al. for the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22
10. Shepherd J, Blauw GJ, Murphy MB, et al. on behalf of the PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled study. Lancet 2002; 360: 1623-30
11. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
12. Gotto AM, Assman G, Carmena R, et al. The ILIB lipid handbook for clinical practice: blood lipids and coronary heart disease. 2nd ed. New York: International Lipid Information Bureau (ILIB), 2000
13. Mas R. Policosanol. Drugs of the Future 2000; 25: 569-86
14. Arruzazabala ML, Carbajal D, Más R, et al. Cholesterol-lowering effects of policosanol in rabbits. Biol Res 1994; 27: 205-8
15. Mendoza S, Gámez R, Noa M, et al. The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res 2001; 62: 209-20
16. Ortensi G, Gladstein H, Valli H, et al. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res 1997; 58: 390-401
17. Mas R, Castaño G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1998; 65: 439-47
18. Castaño G, Más R, Arruzazabala ML, et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int J Clin Pharm Res 1999; XIX: 105-16
19. Castaño G, Más R, Fernández L, et al. Effect of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000; 13: 187-95
20. Mas R, Castaño G, Fernández L, et al. Effects of policosanol in older hypercholesterolemic patients with coronary disease. Clin Drug Invest 2001; 21: 485-97
21. Castańo, G, Mas R, Fernández L, et al. Comparison of the efficacy, safety and tolerability of policosanol versus atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003; 20: 153-63
22. Torres O, Agramonte AJ, Illnait J, et al. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995; 18: 393-7
23. Crespo N, Illnait J, Mas R, et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non insulin dependent diabetes mellitus. Int J Clin Pharmacol Res 1999; XIX: 105-16
24. Castańo G, Fernández L, Mas R, et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidaemia and type 2 diabetes mellitus. Clin Drug Invest 2003; 23: 639-50
25. Menéndez R, Fernández I, Del Río A, et al. Policosanol inhibits cholesterol biosynthesis and enhances LDL processing in cultured human fibroblasts. Biol Res 1994; 27: 199-203
26. Menéndez R, Arruzazabala ML, Más R, et al. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolemia induced by a wheat starch-casein diet. Br J Nutr 1996; 77: 923-32
27. Menéndez R, Amor A, Rodeiro I, et al. Policosanol modulates HMGCoA reductase activity in cultured fibroblasts. Arch Med Res 2001; 32: 8-12
28. Arruzazabala ML, Valdés S, Más R, et al. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res 1996; 34: 181-5
29. Arruzazabala ML, Más R, Molina V, et al. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React 1998; XX: 119-24
30. Menéndez; R, Más R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000; 50: 255-62
31. Menéndez R, Más R, Amor A, et al. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: a randomised, double-blinded pilot study. Curr Ther Res 2000; 61: 609-20
32. Alemán C, Más R, Hernández C, et al. A 12-month study of policosanol oral toxicity in Sprague-Dawley rats. Toxicol Lett 1994; 70: 77-87
33. Rodríguez C, Mesa R, Más R, et al. Effect of policosanol chronically administered in male monkeys (Macaca arctoides). Food Chem Toxicol 1994; 32: 565-75
34. Rodríguez MD, García H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagan 1994; 14: 107-13
35. Mesa AR, Más R, Noa M, et al. Toxicity of policosanol in Beagle dogs: one year study. Toxicol Lett 1994; 73: 81-90
36. Alemán CL, Más R, Noa M, et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24-month study. Teratog Carcinog Mutagan 1994; 14: 239-49
37. Rodríguez MD, Sánchez M, García H. Multigeneration reproduction study of policosanol in rats. Toxicol Lett 1997; 90: 97-106
38. Gámez R, Alemán CL, Mas R, et al. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague Dawley rats. J Med Food 2001; 4: 57-66
39. Harris WS, Park Y, Isley WL. Cardiovascular disease and long chain omega-3 fatty acids. Curr Opin Lipidol 2003; 14: 9-14
40. Lee KW, Lip GV. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM 2003; 96: 465-80
41. Richtner WO. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Eur J Med Res 2003; 8: 332-6
42. Lemaitre RN, King IB, Mozaffarian D, et al. n-3 polyunsaturated fatty acids, fatal ischemic heart disease and non fatal myocardial infarction in older adults: the Cardiovascular Health Study. Am J Clin Nutr 2003; 77: 319-25
43. Hu FB, Bronner L, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-21
44. De Caterina R, Madonna R, Zucchi R, et al. Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. Am Heart J 2003; 146: 420-30
45. Mori TA, Beilin LJ. Long-chain omega 3 fatty acids, blood lipids and cardiovascular reduction. Curr Opin Lipidol 2001; 12: 11-7
46. Clubb FJ, Schmitz JM, Butler JM, et al. Effect of dietary omega-3-fatty acid on serum lipids, platelet function, and atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Arteriosclerosis 1989; 9: 529-37
47. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838-41
48. Friedewald WT, Levy IR, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 1972; 18: 499-502
49. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (L) 1962; 194: 927-30
50. Mori TA, Beilin LJ, Burke V, et al. Interactions between dietary fat, fish and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol 1997; 17: S79-82
51. Kristensen SD, Iversen AM, Schmidt EB. N-3 polyunsaturated fatty acids and coronary thrombosis. Lipids 2001; 36 Suppl.: S79-82
52. Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease: fishing for a natural treatment. BMJ 2004; 32B: 30-5
53. Arruzazabala ML, Carbajal D, Molina V, et al. Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación. Rev Iberoam Tromb Hemost 1992; 5: 17-20
54. Arruzazabala ML, Carbajal D, Molina V, et al. Effect of policosanol on cerebral ischemia in mongolian gerbils: role of prostacyclin and thromboxane A2. Prostagl Leukotr Essent Fatty Acids 1993; 49: 695-7
55. Carbajal D, Arruzazabala ML, Valdés S, et al. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostagl Leukotr Essent Fatty Acids 1998; 58: 61-4
56. Schafer A. Antiplatelet therapy. Am J Med 1996; 101: 199-209
57. Arruzazabala ML, Valdés S, Más R, et al. Comparative study of policosanol, aspirin and the combination of policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 1998; 36: 293-7
58. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995; 15: 247-51